Possibilities of phytotherapy in patients with lower urinary tract symptoms due to benign prostate enlargement

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The results of the use of the phytopreparation Tadimax in the treatment of 60 men with mild and moderate lower urinary tract symptoms (LUTS) developed as a result of benign enlargement of the prostate gland are presented. The average age of the patients was 66.5 ± 3.8 years. Tadimax was prescribed 2 tablets 3 times a day, in courses of 7 days with 7 day breaks for 3 months (a total of 6 courses). The data obtained indicate high efficacy and good tolerability of treatment. A decrease in the severity of LUTS was noted in 59 (96.6%) patients, which was accompanied by significant changes in objective clinical indicators: a decrease in residual urine volume and an increase in urine flow rate. Tadimax is a combined preparation, which includes extracts of several medicinal plants, and the main component is Crinum latifolium. The therapeutic effect of Tadimax is based on anti-inflammatory, antiproliferative and immunotropic action.

Full Text

Restricted Access

About the authors

Adel S. Al-Shukri

Academician I.P. Pavlov First St. Petersburg State Medical University of the Ministry of Healthcare of the Russian Federation

Author for correspondence.
Email: ad330@mail.ru
ORCID iD: 0000-0001-6543-8589

Dr. Sci. (Med.), Professor, Head of the Urological Division No. 1 (General and Urgent Urology) of the Research Center of Urology

Russian Federation, 6/8, Lva Tolstogo street, St. Petersburg, 197089

Stanislav V. Kostyukov

Academician I.P. Pavlov First St. Petersburg State Medical University of the Ministry of Healthcare of the Russian Federation

Email: stanislav.kostyukov57@mail.ru
ORCID iD: 0000-0003-3176-716X

Clinical Resident of Department of Urology

Russian Federation, 6/8, Lva Tolstogo street, St. Petersburg, 197089

References

  1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167-178. https://doi.org/10.1002/nau.10052.
  2. Корнеев И.А., Алексеева Т.А., Аль-Шукри С.Х., Пушкарь Д.Ю. Симптомы нижних мочевых путей у мужчин Северо-Западного региона Российской Федерации: анализ результатов популяционного исследования // Урологические ведомости. – 2016. – Т. 6. – № 1. – C. 5–9. [Korneyev IA, Alexeeva TA, Al-Shukri SH, Pushkar DYu. Lower urinary tract symptoms in male population of the Russian Federation North-Western Region: analysis of population study results. Urologicheskie vedomosti. 2016;6(1):5-9 (In Russ.)]. https://doi.org/10.17816/uroved615-9.
  3. De Ridder D, Roumeguère T, Kaufman L. Urgency and other lower urinary tract symptoms in men aged ≥ 40 years: a Belgian epidemiological survey using the ICIQ-MLUTS questionnaire. Int J Clin Pract. 2015;69(3):358-365. https://doi.org/10.1111/ijcp.12541.
  4. Kogan MI, Zachoval R, Özyurt C, et al. Epidemiology and impact of urinary incontinence, overactive bladder, and other lower urinary tract symptoms: results of the EPIC survey in Russia, Czech Republic, and Turkey. Curr Med Res Opin. 2014;30(10):2119-2130. https://doi.org/10.1185/03007995.2014.934794.
  5. Аль-Шукри С.Х., Кузьмин И.В. Качество жизни больных с гиперактивностью мочевого пузыря // Урологические ведомости. – 2011. – Т. 1. – № 1. – C. 21–26. [Al-Shukri SH, Kuzmin IV. Quality of life in patients with overactive bladder. Urologicheskie vedomosti. 2011;1(1):21-26. (In Russ.)].
  6. Agarwal A, Eryuzlu LN, Cartwright R, et al. What is the most bothersome lower urinary tract symptom? Individual- and population-level perspectives for both men and women. Eur Urol. 2014;65(6): 1211-1217. https://doi.org/10.1016/j.eururo.2014.01.019.
  7. Gravas S, Cornu JN, Gacci M, et al. Management of Non-neurogenic Male LUTS. EAU Guideline. 2020. Available from: https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts. Accessed: Dec 14, 2020.
  8. Martin SA, Haren MT, Marshall VR, et al. Prevalence and factors associated with uncomplicated storage and voiding lower urinary tract symptoms in community-dwelling Australian men. World J Urol. 2011;29(2):179-184. https://doi.org/10.1007/s00345-010-0605-8.
  9. Han L, Kim SP, Gross CP, et al. Association of physicion speciality and medical therapy for Begin prostatic hyperplasia. Med. Care. 2014; 52(2):128-136. Available from: https://www.jstor.org/stable/24465860. Accessed: Dec 14, 2020.
  10. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132(3):474-479. https://doi.org/10.1016/S0022-5347(17) 49698-4.
  11. Guess HA. Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin North Am. 1995;22(2):247-261.
  12. Walsh PC, Hutchins GM, Ewing LL. Tissue content of dihydrotestosterone in human prostatic hyperplasia is not supernormal. J Clin Invest. 1983;72(5):1772-1777. https://doi.org/10.1172/JCI111137.
  13. Nickel JC. Inflammation and Benign Prostatic Hyperplasia. Urol Clin North Am. 2008;35(1):109-115. https://doi.org/10.1016/j.ucl.2007.09.012.
  14. Ficarra V, Rossanese M, Zazzara M, et al. The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy. Curr Urol Rep. 2014;15(12):463. https://doi.org/10.1007/s11934-014-0463-9.
  15. Kramer G, Marberger M. Could inflammation be a key component in the progression of benign prostatic hyperplasia? Curr Opin Urol. 2006;16(1):25-29.
  16. Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol. 2007;51(5):1202-1216. https://doi.org/10.1016/j.eururo. 2006.12.011.
  17. Лоран О.Б., Пушкарь Д.Ю., Раснер П.И. Доброкачественная гиперплазия предстательной железы: принципы консервативной терапии // РМЖ. – 2000. – № 3. – C. 135. [Loran OB, Pushkar’ DYu, Rasner PI. Dobrokachestvennaya giperplaziya predstatel’noj zhelezy: principy konservativnoj terapii. RMJ=Russian Medical Journal. 2000;3:135. (In Russ.)]
  18. Калинина С.Н., Бурлака О.О., Александров М.С., Выдрин П.С. Диагностика и лечение симптомов нижних мочевых путей и эректильной дисфункции у больных доброкачественной гиперплазией предстательной железы // Урологические ведомости. – 2018. – Т. 8. – № 1. – C. 26–33. [Kalinina SN, Burlaka OO, Aleksandrov MS, Vydryn PS. Diagnosis and treatment of lower urinary tract symptoms and erectile dysfunction in patients with benign prostate hyperplasia. Urologicheskie vedomosti. 2018;8(1):26-33. (In Russ.)]. https://doi.org/10.17816/uroved8126-33.
  19. Кузьмин И.В., Аюб А.Х., Слесаревская М.Н. Ингибиторы фосфодиэстеразы 5-го типа в лечении дисфункций нижних мочевых путей // Урологические ведомости. – 2020. – Т. 10. – № 1. – C. 67–74 [Kuzmin IV, Ajub AK, Slesarevskaya MN. Phosphodiesterase type 5 inhibitors in treatment of lower urinary tract dysfunctions. Urology reports (St. Petersburg). 2020;10(1): 67-74. (In Russ.)]. https://doi.org/10.17816/uroved10167-74.
  20. Taub DA, Wei JT. The economics of benign prostatic hyperplasia and lower urinary tract symptoms in the United States. Curr Urol Rep. 2006;7(4):272–281. https://doi.org/10.1007/s11934-996-0006-0.
  21. Пешехонов К.С., Шпиленя Е.С., Бурлака О.О. Значимость фармакоэкономического подхода при выборе лечения гиперплазии предстательной железы // Урологические ведомости. – 2019. – Т. 9. – № 4. – C. 59–72. [Peshekhonov KS, Shpilenia ES, Burlaka OO. Significance of the pharmacoeconomic approach in the choice of treatment of hyperplasia of the prostate. Urologicheskie vedomosti. 2019;9(4):59-72. (In Russ.)]. https://doi.org/10.17816/uroved9459-72.
  22. Аль-Шукри С.X., Горбачев А.Г., Боровец С.Ю., и др. Влияние простатилена на расстройства мочеиспускания у больных доброкачественной гиперплазией предстательной железы // Урология. – 2005. – № 5. – С. 25–26. [Al-Shukri SH, Gorbachev AG, Borovets SJ, et al. Vlijanie prostatilena na rasstrojstva mocheispuskanija u bol’nyh dobrokachestvennoj giperplaziej predstatel’noj zhelezy. Urologiia. 2005;(5):25-26. (In Russ.)]
  23. Кривобородов Г.Г., Тур Е.И. Применение фитотерапии у больных доброкачественной гиперплазией простаты и хроническим простатитом // Медицинский Совет. – 2014. – № 19. – С. 62–63. [Krivoborodov GG, Tur EI. Herbal therapy for patients with benign prostatic hyperplasia and chronic prostatitis. Meditsinskiy sovet = Medical Council. 2014;(19):62-63. (In Russ.)] https://doi.org/10.21518/2079-701X-2014-19-62-63.
  24. Кузьмин И.В., Аль-Шукри С.Х. Простагут-Форте в терапии доброкачественной гиперплазии предстательной железы: патогенетический подход? // Урологические ведомости. – 2012. – Т. 2. – № 3. – C. 18–23. [Kuzmin IV, Al-Shukri SH. Prostagut-Forte in benign prostate hyperplasia therapy: is pathogenic approach? Urologicheskie vedomosti. 2012;2(3):18-23. (In Russ.)]. https://doi.org/10.17816/uroved2318-23.
  25. Doan TN. Crinum latifolium in treatment of benign pypertrophy of prostate and cancers. Journal of Health and Life of Vietnamese Health Ministry. 2002;(148).
  26. Fennell CW, van Staden J. Crinum species in traditional and modern medicine. J Ethnopharmacol. 2001;78(1):15-26. https://doi.org/10.1016/s0378-8741(01)00305-1.
  27. Tram NTN, Titorenkova TzV, Bankova VSt, et al. Crinum L. (Amaryllidaceae). Fitoterapia. 2002;73(3):183-208. https://doi.org/10.1016/s0367-326x(02)00068-0.
  28. Tram NTN, Zvetkova E, Nikolova E, et al. A novel in vitro and in vivo T-lymphocyte activating factor in Crinum latifolium (L.) aqueous extracts. Exp Pathol Parasitol. 1999;(3):21-26.
  29. Yui S, Mikami M, Kitahara M, Yamazaki M. The inhibitory effect of lycorine on tumor cell apoptosis induced by polymorphonuclear leukocyte-derived calprotectin. Immunopharmacology. 1998;40(2): 151-162. https://doi.org/10.1016/s0162-3109(98)00040-x
  30. Jenny M, Wondrak A, Zvetkova E, et al. Crinum latifolium leave extracts suppress immune activation cascades in peripheral blood mononuclear cells and proliferation of prostate tumor cells. Sci Pharm. 2011;79(2):323-336. https://doi.org/10.3797/scipharm.1011-13.
  31. Нусратуллоев И.Н., Одилов А.Ю., Ёров Х.У., Холалиев А.А. Применение лекарственного препарата «Тадимакс» при лечении доброкачественной гиперплазии предстательной железы // Вестник Авиценны. – 2009. – № 4. – С. 41–43. [Nusratulloev IN, Odilov AYu, Yorov HO, Holaliev AA The use of the medicine Tadimax during treatment of benign hyperplasy of prostate. Vestnik Avitsenny [Avicenna Bulletin]. 2009;(4):41-43. (In Russ.)]. doi: 10.25005/2074-0581-2009-11-4-41-43.
  32. Чайка А.В., Бородин А.Д., Черноус В.А., Вербовой П.П. Применение комплексного фитопрепарата «Тадимакс» в лечении доброкачественной гиперплазии предстательной железы // Медико-социальные проблемы семьи. – 2012. – Т. 17. – № 1. [Chaika AV, Borodin AD, Chernous VA, Verbovoi PP. Primenenie kompleksnogo fitopreparata “Tadimaks” v lechenii dobrokachestvennoi giperplazii predstatelnoi jelezi. Mediko-socialnie problemy sem’i. 2012;17(1). (In Russ.)]. Режим доступа: http://www.mif-ua.com/archive/article/35729. Дата обращения: 10.12.2020.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Al-Shukri A.S., Kostyukov S.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ №ФС77-65570 от 04 мая 2016 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies